Kyungbo Pharmaceutical Wins Temporary Injunction Against License Revocation for 23 Prescription Drugs

Reporter Paul Lee / approved : 2025-06-19 03:14:01
  • -
  • +
  • 인쇄

Chong Kun Dang (Photo = Chong Kun Dang)

 

 

[Alpha Biz= Paul Lee] Chong Kun Dang Holdings (KRX: 001630) announced on the 18th that its subsidiary, Kyungbo Pharmaceutical, has obtained a court-issued temporary injunction suspending the effectiveness of an administrative order to revoke marketing authorizations for 23 prescription drug products.



Previously, Kyungbo Pharmaceutical had received a notice of license revocation and business suspension from June 24, following alleged violations of Article 76 (1)-3 and (3) of the Pharmaceutical Affairs Act, involving approximately KRW 13.5 billion worth of prescription drug products.



In response, Kyungbo Pharmaceutical filed for an administrative injunction and a lawsuit to contest the cancellation. On June 16, the court accepted the injunction request and ruled to temporarily suspend the license revocation and the corresponding reimbursement suspension until a final decision on the injunction is made.

 

 

 

Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)

어플

주요기사

NAVER Secures 60,000 NVIDIA Blackwell GPUs to Lead Industrial AI Innovation2025.11.01
Shinhan Investment Raises LG Innotek Target Price to ₩280,000 on Earnings Recovery and 2025 Growth Outlook2025.10.31
Woori Bank Sanctioned by Financial Supervisory Service for Delayed Reporting of Overseas Regulatory Actions2025.10.31
Samyang Foods Raises U.S. Supply Prices for Buldak Ramen Amid Tariff Impact2025.10.31
NH Investment & Securities Suspends IB Executive Under Investigation for Alleged Insider Trading2025.10.31
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

HEADLINE

PHOTO

많이 본 기사